Details for Patent: 10,792,267

Which drugs does patent 10,792,267 protect, and when does it expire?

Patent 10,792,267 protects VASCEPA and is included in one NDA.

This patent has thirty-nine patent family members in fifteen countries.

Summary for Patent: 10,792,267

Title:	Methods of treating mixed dyslipidemia
Abstract:	The present disclosure relates to, inter alia, methods of treating cardiovascular-related disease.
Inventor(s):	Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT), Manku; Mehar (Birmingham, GB)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	16/389,317
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,792,267

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes						USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION, STROKE, BOTH IN AN ADULT PATIENT WITH TYPE 2 DIABETES MELLITUS
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No						USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION, STROKE, BOTH IN AN ADULT PATIENT WITH TYPE 2 DIABETES MELLITUS

International Family Members for US Patent 10,792,267

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010241567
Brazil	PI1014405
Canada	2759176